Physician profile
Steven N Smith
NPI 1033229075
$7,134.96
in general payments reported to CMS, 2019-2025
46 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,066 · 2022: $1,120 · 2023: $1,612 · 2024: $1,761 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,941.51 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,216.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,069.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $822.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $678.74 | 2021-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.68 | 2021-2025 | Jardiance |
| Abbott Laboratories | $336.28 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $266.71 | 2023-2025 | Rexulti |
| Amgen INC. | $261.10 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $249.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $205.05 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $144.67 | 2021-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $130.59 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $124.64 | 2021-2023 | Steglatro, Belsomra |
| Inspire Medical Systems, INC. | $102.97 | 2023-2025 | Inspire |
| Esperion Therapeutics, INC. | $95.45 | 2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.54 | 2022-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $80.34 | 2021-2023 | |
| Exact Sciences Corporation | $71.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $59.36 | 2021-2025 | |
| Dexcom, INC. | $59.05 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $58.49 | 2021-2022 | |
| Lundbeck LLC | $54.67 | 2024-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $54.58 | 2021 | |
| Scilex Pharmaceuticals INC. | $51.44 | 2024 | |
| Sumitomo Pharma America, INC. | $44.21 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $43.59 | 2022-2023 | Quviviq |
| Medtronic, INC. | $35.84 | 2024-2025 | Kyphon Express II Kyphopak Tray, Venaseal |
| Astellas Pharma US INC | $33.16 | 2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $28.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.98 | 2023 | Qelbree, Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $27.93 | 2022-2023 | |
| Halozyme INC | $22.63 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.18 | 2022 | |
| Antares Pharma, INC. | $21.31 | 2023 | Nocdurna, Xyosted, Tlando |
| Axsome Therapeutics, INC. | $20.01 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $19.33 | 2024 | Voquezna |
| Avion Pharmaceuticals | $18.01 | 2023 | Methylphenidate Hydrochloride |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.66 | 2025 | Caplyta |
| Hikma Pharmaceuticals USA | $16.50 | 2024 | Ryaltris |
| Horizon Therapeutics Plc | $16.33 | 2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $15.91 | 2024 | Livalo |
| Alexion Pharmaceuticals, INC. | $14.08 | 2023 | Strensiq |
| Tolmar, INC. | $13.62 | 2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $13.15 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.